Form 4: Axsome COO Mark Jacobson Granted 19,663 Restricted Stock Units

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, was granted 19,663 restricted stock units (RSUs) on February 26, 2026, aligning executive incentives with long-term shareholder value.

Summary

• Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), was granted 19,663 Restricted Stock Units (RSUs).
• The grant date for these RSUs was February 26, 2026.
• Each RSU represents a contingent right to receive one share of Axsome's common stock.
• The RSUs will vest over several years: 25% on the one-year anniversary of the grant date (February 26, 2027), with the remaining RSUs vesting in three substantially equal annual installments, leading to full vesting by February 26, 2030.
• Vested shares will be delivered to Mr. Jacobson upon the earlier of a Change in Control, his separation of service from Axsome, or seven years from the grant date (February 26, 2033).
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this RSU grant positively as it reinforces executive alignment with long-term shareholder value and is a standard practice for retaining key talent in the industry.

Positives

• The RSU grant aligns the Chief Operating Officer's long-term incentives with the company's performance and shareholder interests.
• The vesting schedule encourages long-term commitment and retention of a key executive.
• The grant was made under the Issuer's 2025 Long-Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The issuance of new shares upon RSU vesting will result in a minor dilution of existing shareholder equity, though this is a standard component of equity compensation plans.

Future Outlook

The vesting schedule for the granted RSUs extends through February 26, 2030, indicating a long-term incentive structure for the Chief Operating Officer. The delivery of vested shares is contingent on future events such as a Change in Control, separation of service, or a maximum seven-year period from the grant date.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of equity compensation in the biotechnology and pharmaceutical sectors, particularly for key executives. This practice is designed to align management's financial interests with the long-term success and stock performance of the company, which is crucial in an industry characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The RSU grant to Axsome's COO is consistent with typical executive compensation practices in the biopharmaceutical industry, where equity awards form a significant portion of total compensation.
• Vesting schedules, such as the four-year annual vesting observed here, are standard across many public companies, including peers like Biogen Inc. (BIIB) or Vertex Pharmaceuticals Inc. (VRTX), aiming to retain talent and incentivize sustained performance.
• The inclusion of Change in Control provisions for accelerated vesting is also a common feature in executive compensation plans, providing protection and incentive during potential M&A activities, similar to those seen in agreements at companies like Gilead Sciences, Inc. (GILD).

Related Party Transactions

• The grant of 19,663 Restricted Stock Units to Mark L. Jacobson, the Chief Operating Officer, constitutes a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting, but increased alignment of executive interests with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.
• Management: Provides a significant long-term incentive and compensation component, encouraging retention and performance.

Next Steps

• 25% of the RSUs will vest on February 26, 2027.
• The remaining RSUs will vest in three substantially equal annual installments, with full vesting by February 26, 2030.
• Vested shares will be delivered upon the earlier of a Change in Control, separation of service, or February 26, 2033.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to a company executive, which is a standard compensation practice and does not present new information that would significantly alter the fundamental investment thesis for Axsome Therapeutics. It reinforces management's long-term alignment but is not a catalyst for a 'buy' or 'sell' recommendation on its own.

Keywords

Axsome Therapeutics, AXSM, Restricted Stock Units, RSU grant, Mark Jacobson, Chief Operating Officer, Executive Compensation, Insider Transaction, SEC Form 4, Equity Incentive Plan, Vesting Schedule